Mukurapa kwepamusoro melanoma, budiriro yaive rudzi rutsva rwe immunotherapy, iyo inoshandiswawo muPoland paboka rakasarudzwa revarwere, nyanzvi dzakaziviswa pamusangano wevatori venhau muWarsaw.
Musoro wekiriniki yezvinyoro zvinyoro, bone uye melanoma cancer paOncology Center muWarsaw, Prof. Piotr Rutkowski akataura kuti kusvika munguva pfupi yapfuura, varwere vane melanoma yakakura vanogona kurarama kwehafu yegore. Nekuda kweiyo immunotherapy nyowani, inovhura iyo PD-1 yakarongwa kufa receptor uye inomisa immune system kurwisa cancer maseru, hafu yevarwere vanorarama mwedzi makumi maviri nemana. Vamwe vavo vanorarama kwenguva yakareba.
Mishonga inovharira PD-1 receptor yakanyoreswa muEuropean Union, asi haisati yadzorerwa muPoland. Nekudaro, iwo anowanikwa munyika zhinji dzeEurope, kusanganisira. muSlovakia, Sweden, Czech Republic, Finland, Slovenia, Bulgaria, Ireland, Spain, Denmark, Luxembourg, Austria, Greece neGreat Britain. Kunze kweEU, mishonga iyi inodzoserwawo kuUnited States, Canada, Israel neSwitzerland.
"Tiri kumirira kubhadharwa kwezvigadziriro izvi, nokuti pasina ivo zvakaoma kutaura nezvekurapa kwemazuva ano kwepamusoro metastatic melanoma, kupa vamwe varwere tariro huru yekuwedzera kwehupenyu nekuvandudzwa kwehutano hwayo" - akasimbisa Prof. Rutkowski. Mishonga iyi kazhinji haikonzeri mimwe migumisiro yakakomba.
Kusvika pari zvino, sangano reAgency for Health Technology Assessment and Tariffs rakapa pfungwa yakanaka pamusoro pekudzorerwa kwePD-1 inovharisa mishonga pasi pechirongwa chemishonga pamwe nemamwe marapirwo akatenderwa kurapwa kwechirwere ichi.
Gadziriro dzinosunungura PD-1 receptor, zvisinei, dzinoshandiswa munyika yedu, kusvika zvino pane boka rakasarudzwa revarwere. Prof. Rutkowski vakati panyaya ye<em>melanoma, kusvika pari zvino vakashandiswa muvarwere vanopfuura 200, 100 vavo vachiri vapenyu. Vakabatwa sechikamu chemiedzo yekiriniki kana inodaidzwa kuti Early Access Therapy Program inopihwa mari nemugadziri wezvinodhaka.
“Chirongwa ichi, icho chakatanga muna Kurume 2015, chakapinza varwere 61 vane metastatic melanoma. Kubva muboka iri, varwere makumi matatu vachiri kurapwa "- akadaro Prof. Rutkowski.
National consultant mumunda wekiriniki oncology prof. Maciej Krzakowski, mukuru wekiriniki yekenza yemapapu yeOncology Center muWarsaw, akati mishonga inovhura PD-1 receptor muUnited States neEuropean Union yakabvumidzwawo kurapwa kwegomarara remapapu. MuPoland, iye zvino anowanikwa chete sechikamu chemiedzo yekiriniki.
“Kusvika pari zvino, mishonga yerudzi urwu yave kushandiswa chete semushonga unotevera (danho rechitatu), apo dzimwe nzira dzokurapa dzakatopera. Iye zvino kushandiswa kwavo mumutsara wekutanga kurapwa kuri kufungwa "- akadaro Prof. Krzakowski. Izvi zvinoshandura nzira yekurapa zvirwere zvakadai seyepamusoro melanoma (nhanho IV kana isingashande, nhanho III).
Prof. Krzakowski akatsanangura kuti kenza dzakawanda dzinodzivisa kurwiswa kwemasero ezvirwere zvemurwere. Vanodzivisa kuita kwePD-1 receptor pamusoro pemasero aya (lymphocytes). Vanoshandisa nzira inoshandiswa nemuviri kudzivirira immune system kuti isaite zvehasha (inodzivirira kubva kuzvirwere zve autoimmune).
"Mishonga yechizvarwa chinotevera inovhura PD-1 receptors, ichiita kuti immune system inyatso kuziva uye kurwisa maseru egomarara," akadaro mupi wezano wenyika.
Nyanzvi dzakabvuma pamusangano nevatori venhau kuti hapasati pave nenzira yekuona kuti ndeupi murwere achabatsirwa nemhando iyi yeimmunotherapy. Munyaya ye melanoma, varwere vane kutaura kwakanyanya kwePD-1 receptors vanowanzopindura zviri nani. Muna Zvita 2015, imwe yemishonga yakadai yakabvumidzwawo kurapa gomarara reitsvo muUnited States.
Prof. Krzakowski vakati mhinduro yakanaka ichave iri kupa mari yerudzi urwu rwekurapa nebhajeti rehurumende kana ichinge ichishanda mumurwere akapihwa. Uye zvakare, pane zvakare mukana wekuti mushure menguva yakati kurapwa kwakadai kunogona kuregedzwa mune vangangoita vamwe varwere, apo immune system yaizokwanisa kudzora kukura kweiyo neoplastic chirwere pachayo.
IAmerican Society of Clinical Oncology (ASCO) muna February 2016 yakaziva immunotherapy (kuzarura PD-1 receptor) sekubudirira kukuru mune oncology muna 2015. Izvi zvakashumwa mumushumo wegore we11 "Clinical Cancer Advances 2016". Immunotherapy ichave imwe yemisoro mikuru yeAZSCO yegore negore congress, iyo ichatanga muChicago pakupera kwaMay.